tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront
PremiumThe FlyQ32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront
2M ago
Q32 Bio sells complement inhibitor ADX-097 to Akebia
Premium
The Fly
Q32 Bio sells complement inhibitor ADX-097 to Akebia
2M ago
Q32 Bio Inc. Faces Financial Challenges Amid Development Efforts
Premium
Company Announcements
Q32 Bio Inc. Faces Financial Challenges Amid Development Efforts
2M ago
Eight option delistings on August 18th
PremiumThe FlyEight option delistings on August 18th
5M ago
Q32 Bio Inc. Advances Alopecia Areata Treatment with Phase 2a Trial of Bempikibart
Premium
Company Announcements
Q32 Bio Inc. Advances Alopecia Areata Treatment with Phase 2a Trial of Bempikibart
5M ago
Q32 Bio Inc. Reports Continued Losses Amid Development Efforts
Premium
Company Announcements
Q32 Bio Inc. Reports Continued Losses Amid Development Efforts
6M ago
Q32 Bio Inc. Reports Q1 2025 Financial Results
PremiumCompany AnnouncementsQ32 Bio Inc. Reports Q1 2025 Financial Results
9M ago
Q32 Bio granted Fast Track designation for bempikibart
Premium
The Fly
Q32 Bio granted Fast Track designation for bempikibart
9M ago
Q32 Bio Board Member Mark Iwicki Resigns
Premium
Company Announcements
Q32 Bio Board Member Mark Iwicki Resigns
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100